26 November 2020

The platform that allows researchers to fully exploit available CRC studies is now available

About a year ago Oncode Investigator Louis Vermeulen (Amsterdam UMC) and clinician Miriam Koopman (UMC Utrecht) met at Oncode’s first clinical workshop about colorectal cancer. They knew each other already, but at the workshop they decided to work together to improve prospects for colorectal cancer (CRC) patients.

Bianca-Olivia Nita

The result of their collaboration is the CRC platform (part of the larger BBMRI platform) which connects researchers and clinicians by allowing the sharing of clinical samples to exploit available data to its full potential.

The translation and validation of pre-clinical findings is often hampered and delayed due to unfamiliarity of basic researchers with trial cohorts providing valuable patient materials. But the new and updated CRC platform will contribute to changing that. The platform contains a comprehensive overview of available biomaterials and omics data within clinical studies for CRC. Its aim is to connect fundamental and clinical research and accelerate access to clinical samples (tissue, blood, rest materials) for proof-of-concept and validation studies.

“The colorectal cancer research platform will allow us to efficiently share knowledge and data” says Louis Vermeulen. “This way we can learn from each existing patient how to better treat future patients” he adds.

The core of the new CRC platform is the Dutch Prospective Colorectal Cancer Cohort (PLCRC), a previously existing infrastructure which has now been extended with 17 clinical studies and cohorts encompassing >20,000 biological samples of CRC patients. The newly created platform is available to all researchers within the Oncode community.

“The colorectal cancer research platform is a tool to facilitate collaborations between clinicians and fundamental researchers” says Clara Elbers, Research Manager in the Louis Vermeulen Group. “It is good to see that already in this first phase of building the platform, there is a high commitment from studies and researchers to be involved and contribute to this effort” she adds.

For more information on accessing and using the platform, please contact:

Jacqueline Staring Programme Manager

Other News

Oncode Coverbeeld Q2 2021
Oncode Digital Magazine - April 2021
Welcome to the April edition of our digital magazine! Discover the latest interviews, science stories, latest updates and much more.
Vesnade Jong

<span>Vesna</span><span>de Jong</span>

Vesna is a Digital Content Manager at Lygature, and is responsible for all things digital at Oncode. Originally from Slovenia, where she finished her MA in English language and literature, life led her to the Netherlands. Vesna has more than 10 years of experience in translation and localization, and has gained extensive experience of digital communications while working for one of the biggest online travel agencies.
Lude and Michiel
Oncode Investigators Michiel Vermeulen and Lude Franke receive Vici grant
Oncode is proud to announce that Oncode Investigators Michiel Vermeulen (Radboudumc) and Lude Franke (UMCG) will both receive the Vici grant of 1.5 million euros from the Dutch Research Council (NWO).
PeterThijssen
Ecto org KRT14
First patient-derived organoid model for cervical cancer
Researchers from the group of Oncode Investigator Hans Clevers (Hubrecht Institute) developed the first patient-derived organoid model for cervical cancer. They also modelled the healthy human cervix using organoids. In close collaboration with the UMC Utrecht, Princess Máxima Center for pediatric oncology and the Netherlands Cancer Institute, the researchers used the organoid-based platform to study sexually transmitted infections for a herpes virus. The model can potentially also be used to study the human papillomavirus (HPV), which is one of the main causes of cervical cancer.
Bianca-OliviaNita